A company-published meta-analysis found allogeneic umbilical cord-derived stem cell therapy was associated with lower knee osteoarthritis pain scores at 12 months than corticosteroid and hyaluronic acid injections, the current non-surgical standard.
Longevity Medical Institute published the peer-reviewed review July 6 in Stem Cell Research International. The pooled analysis drew on two controlled trials, one against hyaluronic acid and one, a randomized controlled trial, against a corticosteroid; both favored stem cell therapy, according to a July 10 news release.
Patients receiving the therapy also had lower total Western Ontario and McMaster Universities Osteoarthritis Index scores at 12 months, indicating gains in pain, stiffness and function. Researchers found no clear signal of severe treatment-related adverse events but said larger randomized trials are needed on long-term safety and dosing.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
